TD Cowen 46th Annual Health Care Conference
Logotype for Senti Biosciences Inc

Senti Biosciences (SNTI) TD Cowen 46th Annual Health Care Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Senti Biosciences Inc

TD Cowen 46th Annual Health Care Conference summary

3 Mar, 2026

Key technology and therapeutic approach

  • Logic-gated cell therapies selectively kill cancer cells while sparing healthy cells, addressing a major challenge in oncology treatment.

  • SENTI-202 is an off-the-shelf allogeneic NK cell therapy targeting CD33 and FLT3, covering over 95% of AML patients.

  • The therapy uses an activating CAR for cancer targets, an inhibitory CAR for healthy cells, and IL-15 to enhance NK activity.

  • Logic-gating technology is adaptable to both NK and T cells and is being explored for solid tumors.

  • SENTI-202 is not genetically restricted, allowing broad patient eligibility.

Clinical data and outcomes

  • In a phase I study with relapsed/refractory AML patients, SENTI-202 achieved a 50% overall response rate and 42% CR/CRh at RP2D, with a 7.6-month median duration of CRs.

  • 100% of CRs were MRD negative, indicating deep responses and potential for improved patient outcomes.

  • The safety profile was favorable, with most adverse events related to lymphodepletion and manageable; no significant CRS observed.

  • Responses were observed across patients with adverse genetic features and those refractory to prior therapies.

  • Outpatient dosing is feasible, and the product is suitable for rapid delivery due to its off-the-shelf nature.

Mechanism of action and differentiation

  • SENTI-202's logic gate design enables selective killing of AML blasts and leukemic stem cells while sparing healthy hematopoietic stem cells.

  • CyTOF analysis confirmed maintenance or increase of healthy stem cells in responders, supporting the logic gate's function.

  • The therapy is effective even in patients with high-risk genetics, including complex karyotypes.

  • The approach is differentiated from existing therapies by not requiring specific genetic mutations and by targeting both AML blasts and stem cells.

  • The technology is being adapted for solid tumors, with proof-of-concept shown for CEA-positive cancers using a NOT gate to protect healthy cells.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more